FIELD: biotechnology.
SUBSTANCE: invention relates to biotechnology, in particular, to new compositions of nucleic acid molecules encoding the modified consensus antigen MUC16, and can be used in medicine. Disclosed is a new modified consensus antigen MUC16, and a possibility of application thereof as a tumour marker is demonstrated.
EFFECT: production of safe and effective combined vaccines applicable against MUC16-expressing tumours thereby providing treatment and contributing to the survival of subjects affected by such types of cancer.
31 cl, 30 dwg, 28 tbl, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTI-CANCER VACCINES TARGETING MUC16 AND THEIR USE | 2018 |
|
RU2750689C1 |
| MESOTHELINE-TARGETED CANCER VACCINES AND THEIR APPLICATION | 2018 |
|
RU2751252C1 |
| IMMUNOGENS FOR VACCINATION AGAINST HIV | 2013 |
|
RU2721274C2 |
| ANTIBODIES TO MUC16 AND THEIR APPLICATION | 2016 |
|
RU2758113C2 |
| ISOLATED RECOMBINANT VIRUS BASED ON INFLUENZA VIRUS FOR INDUCING SPECIFIC IMMUNITY TO INFLUENZA VIRUS AND/OR PREVENTING DISEASES CAUSED BY INFLUENZA VIRUS | 2021 |
|
RU2813150C2 |
| ANTI-CANCER VACCINES AIMED AT LEMD1 AND THEIR USE | 2018 |
|
RU2760984C1 |
| AFRICAN SWINE FEVER VACCINE | 2020 |
|
RU2819672C2 |
| IMMUNOTHERAPY USING ANTIBODIES BINDING PROGRAMMED CELL DEATH PROTEIN LIGAND 1 (PD-L1) | 2017 |
|
RU2766582C2 |
| CHIMERIC PROTEIN, A SYNTHETIC DNA WHICH CODES SAID PROTEIN, AN EXPRESSION VECTOR, A SYNTHETIC DNA PRODUCING STRAIN AND A METHOD OF PRODUCING PLASMID DNA | 2016 |
|
RU2736472C2 |
| IMMUNOTHERAPY USING ANTIBODIES BINDING PROTEIN 1 OF PROGRAMMED CELL DEATH (PD-1) | 2017 |
|
RU2768404C2 |
